{"id":"cefamandole-nafate","rwe":[{"pmid":"41272089","year":"2025","title":"Repurposing cephalosporins as excellent anticancer agents and chemosensitizers for inflammation-driven cancer therapy.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41259247","year":"2025","title":"Compatibility and stability of seven selected cephalosporin antibiotics during extended infusion.","finding":"","journal":"Science progress","studyType":"Clinical Study"},{"pmid":"39315412","year":"2024","title":"Research on Drug Efficacy using a Terahertz Metasurface Microfluidic Biosensor Based on Fano Resonance Effect.","finding":"","journal":"ACS applied materials & interfaces","studyType":"Clinical Study"},{"pmid":"36114650","year":"2022","title":"Impurity profile and spectrum characteristics of the isomers in cefamandole nafate using high- performance liquid chromatography/high-performance size exclusion chromatography tandem ion trap/time-of-flight mass spectrometry.","finding":"","journal":"Rapid communications in mass spectrometry : RCM","studyType":"Clinical Study"},{"pmid":"29579634","year":"2018","title":"Separation and characterization of allergenic polymerized impurities from cephalosporin for injection by trap free two-dimensional high performance size exclusion chromatography × reversed phase liquid chromatography coupled with ion trap time-of-flight mass spectrometry.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"}],"tags":[{"label":"cefamandole nafate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Lilly","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Eli Lilly","patents":[],"pricing":[],"allNames":"kefadol","offLabel":[],"synonyms":["cefamandole nafate","cefamandole formate sodium","cephamandole nafate","kefadol","kefandol","lampomandol","neocefal"],"timeline":[{"date":"1978-09-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Lilly)"},{"date":"1985-09-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Kefadol, also known as cefamandole nafate, is a small molecule antibiotic in the cefamandole class. Originally developed by Lilly and currently owned by the same company, it was FDA approved in 1978. Although its target and exact mechanism of action are unknown, it is used to treat various bacterial infections. Kefadol is now off-patent and available as a generic medication. As with any antibiotic, it is essential to use Kefadol judiciously to prevent the development of antibiotic-resistant bacteria.","brandName":"Kefadol","ecosystem":[],"mechanism":{"target":"Bacterial penicillin-binding protein","novelty":"Follow-on","modality":"Small Molecule","drugClass":"cefamandole nafate","explanation":"Imagine the bacterial cell wall as a strong, protective shield. Kefadol disrupts the process of building this shield, causing the bacteria to weaken and eventually die. This allows the body's immune system to fight off the infection more effectively.","oneSentence":"Kefadol works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Cefamandole nafate exerts its antibacterial effects by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the transpeptidation reaction necessary for cell wall synthesis and ultimately leading to cell lysis and death."},"commercial":{"launchDate":"1978","_launchSource":"DrugCentral (FDA 1978-09-27, LILLY)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/528","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEFAMANDOLE%20NAFATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFAMANDOLE NAFATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:12:36.958735","biosimilars":[],"competitors":[{"drugName":"amoxicillin","drugSlug":"amoxicillin","fdaApproval":"1974-12-09","patentExpiry":"May 7, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"ampicillin","drugSlug":"ampicillin","fdaApproval":"1965-12-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bacampicillin","drugSlug":"bacampicillin","fdaApproval":"1980-12-22","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"benzathine benzylpenicillin","drugSlug":"benzathine-benzylpenicillin","fdaApproval":"1952-06-27","relationship":"same-target"},{"drugName":"benzylpenicillin","drugSlug":"benzylpenicillin","fdaApproval":"1947-02-06","relationship":"same-target"},{"drugName":"carbenicillin","drugSlug":"carbenicillin","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"carindacillin","drugSlug":"carindacillin","fdaApproval":"1972-10-26","relationship":"same-target"},{"drugName":"cefaclor","drugSlug":"cefaclor","fdaApproval":"1979-04-04","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"cefadroxil","drugSlug":"cefadroxil","fdaApproval":"1978-02-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"cefalexin","drugSlug":"cefalexin","fdaApproval":"1971-01-04","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cefamandole nafate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"amoxicillin","brandName":"amoxicillin","genericName":"amoxicillin","approvalYear":"1974","relationship":"same-target"},{"drugId":"ampicillin","brandName":"ampicillin","genericName":"ampicillin","approvalYear":"1965","relationship":"same-target"},{"drugId":"bacampicillin","brandName":"bacampicillin","genericName":"bacampicillin","approvalYear":"1980","relationship":"same-target"},{"drugId":"benzathine-benzylpenicillin","brandName":"benzathine benzylpenicillin","genericName":"benzathine benzylpenicillin","approvalYear":"1952","relationship":"same-target"},{"drugId":"benzylpenicillin","brandName":"benzylpenicillin","genericName":"benzylpenicillin","approvalYear":"1947","relationship":"same-target"},{"drugId":"carbenicillin","brandName":"carbenicillin","genericName":"carbenicillin","approvalYear":"","relationship":"same-target"},{"drugId":"carindacillin","brandName":"carindacillin","genericName":"carindacillin","approvalYear":"1972","relationship":"same-target"},{"drugId":"cefaclor","brandName":"cefaclor","genericName":"cefaclor","approvalYear":"1979","relationship":"same-target"},{"drugId":"cefadroxil","brandName":"cefadroxil","genericName":"cefadroxil","approvalYear":"1978","relationship":"same-target"},{"drugId":"cefalexin","brandName":"cefalexin","genericName":"cefalexin","approvalYear":"1971","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"NUI":"N0000179072","MMSL":"4370","NDDF":"002725","UNII":"8HDO7941DO","VUID":"4017539","CHEBI":"CHEBI:3481","VANDF":"4017539","RXNORM":"203480","UMLSCUI":"C0054995","ChEMBL_ID":"CHEMBL1201218","KEGG_DRUG":"D00909","DRUGBANK_ID":"DB14725","PUBCHEM_CID":"23665731","SNOMEDCT_US":"48172009","MESH_SUPPLEMENTAL_RECORD_UI":"C012810"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1978-","companyName":"Eli Lilly","relationship":"Original Developer"}],"publicationCount":91,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Lilly","recentPublications":[{"date":"2025 Nov 21","pmid":"41272089","title":"Repurposing cephalosporins as excellent anticancer agents and chemosensitizers for inflammation-driven cancer therapy.","journal":"Scientific reports"},{"date":"2025 Oct-Dec","pmid":"41259247","title":"Compatibility and stability of seven selected cephalosporin antibiotics during extended infusion.","journal":"Science progress"},{"date":"2024 Oct 2","pmid":"39315412","title":"Research on Drug Efficacy using a Terahertz Metasurface Microfluidic Biosensor Based on Fano Resonance Effect.","journal":"ACS applied materials & interfaces"},{"date":"2022 Dec 15","pmid":"36114650","title":"Impurity profile and spectrum characteristics of the isomers in cefamandole nafate using high- performance liquid chromatography/high-performance size exclusion chromatography tandem ion trap/time-of-flight mass spectrometry.","journal":"Rapid communications in mass spectrometry : RCM"},{"date":"2018 May 30","pmid":"29579634","title":"Separation and characterization of allergenic polymerized impurities from cephalosporin for injection by trap free two-dimensional high performance size exclusion chromatography × reversed phase liquid chromatography coupled with ion trap time-of-flight mass spectrometry.","journal":"Journal of pharmaceutical and biomedical analysis"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Lilly"],"status":"approved","companyName":"Eli Lilly","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"1978","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}